The antiviral role of type I IFN was shown in vivo: antiinterferon sera administration increased dramatically the susceptibility to acute challenges with lymphocytic choriomeningitis, encephalomyocarditis, herpes simplex, maloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses. Mice impaired for the IFN-␣/-␤ receptor were extremely susceptible to acute challenges with vesicular stomatitis, Semliki Forest, vaccinia, or the noncytopathic lymphocytic choriomeningitis WE strain viruses [7] [8] [9] [10] . IFN-␣ is currently widely used to treat viral hepatitis B and C [11] . A transitory peak of type I IFN was found in the plasma of SIV-infected macaques around day 10 postinfection, concomitant to the peak of plasma viral load [12] . In draining lymph nodes from rhesus macaques infected intravaginally by SIV mac -251 or -239 , elevated IFN-␣ mRNA levels susceptible to have an antiviral activity were found too late to prevent viral replication and dissemination, whereas pro-inflammatory cytokine mRNA susceptible to recruit potential targets for SIV were found earlier [13, 14] .When patients were studied during primary infection, on average 2 months postinfection, type I IFN was not detectable in the plasma, at least by conventional methods in our hands [15] .
The capacity of natural interferon producing cells (NIPC) within PBMC to produce IFN-␣ in vitro in response to stimulation by HSV-1 or other viral stimulation is impaired in association with occurrence of opportunistic infections and Kaposi sarcoma [16 -23] . Conversely, IFN-␣ production is higher in asymptomatic long-term survivors than in uninfected controls [24] . It is dramatically impaired during primary infection [15] , adding another subclinical tendency toward immune deficiency to those that are already known during this stage, like low CD4 T cell counts [25] . This impairment was less pronounced after a follow-up of 1 year in untreated patients, but it was corrected in highly active antiretroviral therapy (HAART) treated patients [15] . This effect of HAART needs to be assessed in a larger cohort of patients. Primary infection is the stage in which a balance is set between viral replication and immune responses, depending on viral strain characteristics and host genetic factors [26] . The future evolution of these patients will tell whether the loss of IFN production in vitro during this stage is detrimental for the outcome of the disease. In chronically infected, progressive patients, reconstitution of IFN-␣ production, associated with protection from recurrent or opportunistic infection, was obtained by HAART [27] . Interestingly, this restoration occurred earlier than that of CD4 T cell counts [28] . Overall, a correlation seems to appear between high IFN-␣ production capacities and low HIV viral loads and high CD4 cell counts and lack of opportunistic infections [24, 27, 29] These correlations can be related to the direct antiviral role of IFN-␣ or -␤ on HIV-1 infected cells in different models using severe combined immunodeficient mice [30 -33] .
Type I IFN activation and mechanisms of action HIV-1 stimulates plasmacytoid dendritic cells (pDC) through TLR7 [34] and apparently CD4 [35] . Induction of type I IFN by viruses can also be mediated through binding of viral RNA or DNA to TLR3, -8, or -9. Induction of type I IFN through TLR7, -8, and 09 is mediated by the adaptor molecule myeloid differentiation primary response protein 88 (MyD88), inter-feron regulatory factor (IRF)-7 and finally NF-B activation. Induction of type I IFN by viruses can also be mediated through TLR-independent pathways, involving cytoplasmic sensors, like the retinoic acid-inducible gene I (RIG-I) and the melanoma differentiation-associated gene 5 (MDA5). This leads to IRF3 activation and finally NF-B activation [36] .
Type I IFNs induce or enhance the expression of many genes [37] through a cell transmembrane receptor composed of two subunits, IFNAR1 and IFNAR2. Binding of the receptors leads to a cascade of phosphorylation of kinases , JAK1 and Tyk2, and subsequently to the tyrosine phosphorylation of signal transducers and activators of STAT1 and STAT2. These activated STAT form a complex with IRF9, ISGF3, which translocates to the nucleus and binds to DNA sequences of IFNstimulated genes (ISG) containing IFN-stimulated response elements (ISRE). More than 100 ISG are transcribed, and their products are involved in the different properties of interferons such as antiviral, antiproliferative, apoptosis, and immunomodulatory properties. The main ISG encode for the protein kinase is stimulated by ds RNA (PKR), the 2Ј-5Јoligoadenylate synthetases (OAS), and the myxovirus resistance GTPase (MX), but also the ISG 20. PKR is a serine threonine kinase, which, in the presence of dsRNA, phosphorylates substrates, among which the subunit ␣ of the eukaryotic initiation factor 2-␣ (eIF2␣) stops protein translation. OAS, in the presence of dsRNA, synthetize 2Ј5Ј oligoadenylates, which activate endogenous cytoplasmic RNase L (RNase L) and lead to the degradation of viral and cellular mRNA. PKR and OAS are also involved in cellular apoptosis. The antiviral activity of MxA, from the dynamin family, inhibits the RNA polymerase of influenza viruses but also acts against other viruses by a different, unexplained pathway [36] . The antiviral activity of type I IFN can also be mediated by different actors of the immune system [3, 36] . Indeed, type I IFNs amplify their own expression through induction of IRF-7
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[48] and through accumulation of pDC [49] . They activate the lytic potential and proliferation of NK and ␥␦ T cells and NO synthesis by macrophages. They also enhance lysis of infected cells by cytotoxic T cells or T helper type 1 cells, as well as IFN-␥ production by T lymphocytes [50] . They increase class I MHC expression on all cell types, perhaps counteracting the effect of HIV Nef [51, 52] and thus potentially increasing recognition and lysis by specific CD8ϩ T lymphocytes. In addition, cross-presentation by DC is enhanced through the action of virally induced type I IFN [53] , and this presentation pathway is probably crucial so as to enhance viral antigen presentation while avoiding autoimmune recognition [54 -58] . Conversely, high levels of type I IFN inhibit IL-12 expression and IL-12 activation of NK cell IFN-␥ production [50] . STAT1 has a critical role in many of these effects [36] . [59] . The HIV-1 transactivating response (TAR) RNA can activate the 2-5A synthetase and PKR [60] . However, HIV induces the expression of the RNase L inhibitor, which antagonizes the binding of 2Ј-5ЈA oligoadenylates to RNase L [61] . PKR can be activated by HIV through binding to the ds RNA region TAR of the LTR [62] . The transactivating protein Tat and the cellular TAR RNA binding protein (TRBP) also bind to TAR and to PKR and behave as inhibitors of the autophosphorylation of PKR during viral infection, therefore inhibiting its action on the eIF2␣ substrate and hence inhibition of protein synthesis. TRBP is part of a DICER complex and is required for RNA interference; it is perhaps diverted by HIV-1 [63] [64] [65] . Moreover, PKR can phosphorylate HIV Tat and enhance its capacity to transactivate the LTR [66] . TAR and Tat, therefore, participate actively in viral escape to the effects of type I IFN.
Viral escape to the effects of type I IFN

ADVERSE ROLES OF TYPE I IFN IN VIRAL INFECTION
All the effector mechanisms of the immune system that reduce viral replication have mirroring adverse effects on the host. Type I and type II IFNs induce a cytotoxic activity in antigen presenting cells. HIV itself, like other viruses, induces a cytotoxic activity in monocytes [67] , DC [68] , and CD4 T cells themselves [35] against infected CD4 T lymphocytes but also against uninfected cells. TRAIL mediates at least in part the cytotoxicity of monocytes, in a type I IFN-dependent way [69] . In vitro, HIV-1 gp120 induces in CD4 T lymphocytes both sensitivity to TRAIL directly and TRAIL expression indirectly, through the stimulation of CD4, which induces type I IFN secretion by pDC [35] . These cytotoxic mechanisms, as well as those stimulated in NK cells [70] or bystander T cells, can be responsible for the high susceptibility to apoptosis of uninfected CD4 T cells that are found in HIV-infected patients [71] . Indeed, TRAIL neutralization in HIV-1 infected Hu-PBL-NOD-SCID mice inhibits human CD4 T cell apoptosis induced by HIV-1 infection [72] . Moreover, soluble TRAIL is found in the plasma of HIV-1 infected patients and is decreased by HAART in correlation with viral load [69] . In addition, in the SCID-hu Thy/liv mouse model and in thymus organ cultures, HIV-1 induces pDC to secrete type I IFN, which in turn up-regulates MHC class I molecule expression on most thymocytes [73] . This may lead to thymic selection of dysfunctional CD8ϩ T lymphocytes [74] . High thymic IFN levels may also be at least partly responsible for the reduction in intrathymic proliferation found in primary infection [75] .
Early work has suggested a deleterious effect of high concentrations of IFN-␣ (i.e., inhibition of T cell proliferation, inhibition of chemokine production) and even proposed immunization against this cytokine as a therapeutic approach against AIDS [76, 77] . A dichotomy may exist between positive and negative effects of IFN-␣ in the early vs. late stages of the disease. IFN-␣ has been shown to be potentially beneficial on HIV viral loads during early stages of infection, but not later [78] . In chronic lymphocytic choriomeningitis virus (LCMV) infection, administration of anti-IFN serum inhibits pathogenesis [79] . Besides their effects in viral infections, type I IFN can enhance autoimmunity; particularly, the high levels of type I IFN found in the sera of systemic lupus erythematosus induce differentiation of monocytes into DC and probably exacerbate the pathogenesis of the disease [80, 81] .
PLASMACYTOID DENDRITIC CELLS AND OTHER CELL TYPES RESPONSIBLE FOR TYPE I IFN PRODUCTION
The major human peripheral blood mononuclear cell subset that was responsible for the production in vitro of IFN-␣ in response to influenza, Sendai, and Newcastle disease viruses was first identified as an HLA-DR ϩ , DC-related population lacking the markers for other cell lineages [82, 83] . This population was nonadherent and stimulated allogeneic T cell proliferation poorly [84] . NIPC or IPC were eventually identified as plasmacytoid dendritic cells (pDC) [85] [86] [87] [88] [89] . They are present in lymph nodes, tonsils, and blood with a very low frequency and they produce 100 times more type I IFN per cell than monocytes [90, 91] .When they are depleted in vivo, the response to mCMV infection or to CpG or oligoribonucleotide injection is abolished [92] [93] [94] [95] . In some infections, like LCMV infection, pDC are not the major population responsible for the early IFN-␣ response [93] . In humans [96, 97] , pDC produce IFN-␣ [98] after stimulation by live or inactivated HIV [99, 100] . IFN-␣ in turn sustains pDC survival [101, 102] . pDC counts are reduced during chronic as well as primary HIV-1 infection [22-24, 27, [103] [104] [105] [106] [107] . A correlation with plasma viral load [24, 27, 103] and/or with peripheral CD4 T cell counts [103, 105, 106, 108] was found in most, but not all, studies [22, 105] . A correlation with lymphoproliferative responses against HIV-1 p24 was found in one study [105] . In a pediatric study, pDC counts were found to be lower in viremic children with a history of decreasing CD4 T cell percentages compared with children with stable CD4 T cell counts [106] . The pDC count defect is already found at the onset of primary infection. Strikingly, at the onset of primary HIV infection and not at later time points in HIV or HCV [109] infection, the correlation between pDC counts and type I IFN production is lost [15] , indicating loss of function in some pDC.
Why are circulating pDC numbers reduced in HIV patients? A central bone marrow precursor defect may be involved, as for T lymphocyte precursors in macaques [110, 111] . pDC may also be destroyed in the periphery by the virus itself. Indeed, HIV infects pDC in vitro with cytopathogenicity [99, 112, 113] , and infected pDC are found in the tonsils, thymus, and blood from HIV-infected patients [114, 115] . pDC may also strive less because of lower IFN production [29] or defective interaction with CD4 T lymphocytes [115] . In any case, pDC were probably home to lymph nodes during HIV infection [116 -118] . In the SIV infection model, many activated DC were found in lymphoid tissues in primary or asymptomatic infection, but at the stage of AIDS only few activated CD83 ϩ DC were found in the lymph nodes [118] . This finding was consistent with the lower capacity to up-regulate this terminal differentiation molecule on spleen DC from late-stage HIV-infected patients [119] .
Thus, the mechanisms responsible for the loss of circulating DC are not identified but may reflect different mechanisms, including homing to the lymphoid organs. This homing may help induce antiviral responses on one hand and hyperactivation of the immune system on the other; whereas a lack of DC activation in the lymphoid organs may reflect the failure of the immune system in AIDS.
HOMING AND CELL INTERACTION
Compartmentalization is a key to understanding all biological responses, including immune responses. Type I IFN production will occur where the pDC are driven by viral stimulation, and relevant data must be sought not only in blood but also in lymphoid organs [120 -122] . Migration of DC upon stimulation is selectively driven by the successive expression of different chemokine receptors and integrins [123] . Human pDC express L-selectin (CD62L), which probably drives their entry into the lymph nodes through high endothelial venules in the steady state [86, 124, 125] . During bacterial-or viral-driven inflammation, the expression of CXCR3 is required for pDC migration into the lymph nodes in a CXCL9-and E-selectin-dependent manner [126] . Plasmacytoid DC migration into inflamed tissues or tumors can also be mediated by CXCR4 and driven by SDF-1/CXCL12 [127] ; ChemR23; chemerin [128] ; and CCR1, CCR2, and CCR receptors for inflammatory cytokines [91] . Once activated, pDC express CCR7, the receptor for the chemokines MIP3␤/CCL19 and SLC or 6Ckine/CXCL19, which attract them into the T cell areas of secondary lymphoid organs [129] . In HIV infection, homing of pDC to the lymph nodes [116] would be consistent with the in vitro induction by HIV-1 of CCR7 expression and of migration toward CCL19 [130] . In mice, pDC differ from mDC in the in vivo response to TLR ligands, in terms of pattern and type I IFN requirement for activation and migration [131] .
Human pDC have a successive chemokine expression pattern susceptible to attract other cell populations-first effector cells (cytotoxic T and NK cells and neutrophils), then effector memory T cells, then naive T and B lymphocytes-while they mature and putatively progress toward the T cell zones of the secondary lymphoid organs [132] [133] [134] [135] . In addition, the crosstalk between mDC, pDC, monocytes, T and B lymphocytes, neutrophils, and NK cells in HIV infection needs to be explored [106, 107, 136 -138] . The relations between pDC and the regulatory T cells that hinder antiviral effector responses as well as pathogenic hyperactivation of the immune system in HIV and SIV infections [139 -145] will be interesting to study, because pDC can induce regulatory T cells [146 -148] . Indeed, semi-mature pDC and mDC and FoxP3 ϩ
CD4
ϩ T cells were found in the lymph nodes from untreated HIV ϩ patients in higher proportions than in lymph nodes from treated HIV ϩ patients or from HIV -patients [149] . CCR5-and CXCR4-using HIV-1 isolates stimulate pDC maturation (upregulation of CD83, CCR7, costimulation molecules, migration toward CCL19) and secretion of TNF-␣ and IFN-␣ [99, 130, 150] . In contrast, in response mostly to CCR5-using HIV-1 isolates, depending on the laboratories and probably on the concentration used, mDC undergo at least partial maturation but do not secrete either type I IFN nor bioactive IL-12 p70 [150, 151] . However, when pDC and mDC are co-cultured with HIV, IFN and TNF-␣ secretion by pDC induces mDC maturation [130] . Virus replication is enhanced after pDC treatment with CD40L and antibodies against IFN-␣, probably because of the reduction in IFN-␣ production [113, 114] . HIV-1 infection is transferred from pDC as well as from mDC, most efficiently toward antigen-specific CD4 ϩ T cells [152] .
PREDICTIVE FACTORS DURING HIV INFECTION
The results described above hint that pDC counts (when they will be standardized [15] ) and/or in vitro type I IFN production might be used as predictive factors during HIV infection, as well as in other infections. Indeed, in dengue virus infection, children who developed hemorrhagic dengue fever had an early decrease in circulating pDC levels, which was not found in those who had more benign forms of the disease [153] . In tuberculosis, pDC count recovery correlates with successful antibiotic treatment [154] . Other predictive factors in HIV infection include: baseline levels of CD4 T cell counts and plasma HIV RNA; the nadir CD4 T cell count, as well as parameters such as CD4 T cell counts; proviral DNA load in peripheral blood mononuclear cells; anti-p24 lymphoproliferative response at the time of treatment interruption; and immunologic setpoint activation, as measured by median density of CD38 molecules on CD4 and CD8 T cells [155] [156] [157] [158] [159] [160] . However, these factors are not completely predictive of disease progression in at least three circumstances.
First, the decision was to treat by HAART early during acute or primary infection. Here, the putative restoration of type I IFN production under HAART adds an additional argument, together with the reduction of CD8 T cell oligoclonality [161] and the increase in specific CD4 responses [162, 163] , for the use of HAART to preserve the immune system while viral populations are homogeneous, thus preventing virus spreading. However, there is limited durability [164] , early resistance induction [160, 165] , long-term drug-associated toxicities, and lack of adherence [26] .
Second, HAART success was evaluated: a recovery in pDC counts, at least partial, or in type I IFN production, was obtained in several studies but not all [22] , through HAART during chronic infection [27, 108] and probably during primary infection [15, 166] . This recovery sometimes correlated with a recovery in CD4 T cell counts and/or a decrease in viral load [27, 104, 108] . pDC count recovery was earlier and more pronounced than CD4 count recovery [28, 108] .
Third, patients who requested HAART interruption because of side effects were counseled. One study on patients with primary HIV-1 infection with undetectable viral loads under HAART showed that pDC count recovery during HAART correlated with the ability to control spontaneously replication after treatment interruption [166] . This pilot study needs further confirmation in large cohorts of chronically infected patients [158] . pDC counts, in addition to baseline viral load and other predictive factors, might factor in counseling the patients on their risk of viral replication rebound.
TYPE I IFN ADMINISTRATION OR STIMULATION AS THERAPY AGAINST HIV INFECTION
IFN-␣ is currently being tested in clinical trials, particularly during primary HIV infection, where it might supplement defective production [15] and where promising results were obtained [167] , as formerly in asymptomatic chronic infection [78] . Type I IFN production might also be stimulated by TLR ligands, if pDC can still respond. More interestingly, it might be stimulated by CpG or imiquimod analogs for antiviral protection at the mucosal level [168 -170] . However, caution must be exercised to avoid hyperactivation of the mucosal immune system that would increase viral replication [171] . Finally, IFN-␣ is a strong adjuvant in vaccination [172] . It induces the differentiation of monocyte-derived DC for cell therapy [173, 174] . CpG oligonucleotides can stimulate not only pDC, but also B cells [175] , for systemic and mucosal vaccination; indeed they induce strong local T cell immune responses in the genital tract and cross-clade protection [176, 177] . Therefore, type I IFN administration or stimulation may have a strong potential in future immune therapies against HIV.
CONCLUSION
Correlative data indicate that type I IFN produced by pDC have a role in the control of HIV infection, although pathogenicity may also be induced [178 -186] . The role of homing into lymphoid organs and of interactions with other cell types still needs intensive studying during this infection. Plasmacytoid DC counts and/or of type I IFN production tests in vitro might be used as predictive factors during HIV infection, to evaluate HAART success or to counsel patients who want to interrupt HAART about their risk of viral rebound. Immune therapy and vaccination can use either IFN-␣ itself or its induction by TLR ligands to obtain better viral replication control and stimulation of antigen-specific immune responses. The mechanisms of viral escape to the effects of type I IFN need to be understood further to lead to better targeted therapies. 
